摘要
目的探讨胃肠道间质瘤（gastrointestinal tromal tumors,GIST）患者的临床特点、病理特征及影响预后的治疗方法。方法收集青岛大学附属医院2008年1月-2013年5月确诊的GIST患者174例,回顾性分析患者的临床特点、病理特征及影响预后的治疗方法。结果免疫组化检测结果显示174例GIST患者CD117阳性率58.6%（102/174）,阳性染色在细胞膜或胞浆;CD34阳性率41.4%（72/174）,阳性染色定位于细胞膜或胞浆;SMA阳性率7.5%（13/174）,阳性染色定位于细胞浆;S-100阳性率1.7%（3/174）,阳性染色定位于细胞核或胞浆。术后高危患者应用伊马替尼治疗3~12个月,其用药时间越长,生存率越高。结论GIST临床特点独特,CD117、CD34是诊断GIST的特异指标,患者生存率的高低与应用伊马替尼时间有一定的相关性。
Objective To study clinical features, pathological characteristics, treatment and the prognosis of the pa- tients with gastrointestinal stromal tumor （GIST）. Methods One hundred and seventy-four cases of GIST in the Affilia- ted Hospital of Qingdao University from Jan. 2008 to May. 2013 were collected. The clinical features, pathological characteristics and treatment of influencing the prognosis were analyized by reviewing medical literature. Results Immu- nohistochemical detection showed that CDl17 positive rate was 58.6% （102/174） which positive staining was in the cell membrane and cytoplasm; CD34 positive rate was 41.4% （72/174） which positive staining was in the cell membrane and cytoplasm;SMA positive rate was 7.5% （13/174）which positive staining was in cell plasma ;S - 100 positive rate was 1.7% （3/174） , which positive staining was in the nucleus or cytoplasm. The high-risk patients were treated with imatinib for 3 ~ 12 months, with the longer of imatinib, the surival rate was higher. Conclusion The clinical features of GIST is unique, CD117, CD34 are specific indexes for diagnosis of GIST. The application level and the survival rate of patients with imatinib mesylate time have certain correlation.
出处
《胃肠病学和肝病学杂志》
CAS
2015年第6期728-730,共3页
Chinese Journal of Gastroenterology and Hepatology
关键词
胃肠道间质瘤
临床特征
免疫组化
伊马替尼
Gastrointestinal stromal tumors
Clinical features
Immunohistochemical
Imatinib
